GlassScriptPhysician profile
Lori Kay
NPI 1447703251
$9,021.20
in general payments reported to CMS, 2019-2025
17 companies · $2,708 in 2025
The $2,708 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $1,520 · 2023: $1,739 · 2024: $2,242 · 2025: $2,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,413 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,412.85 |
| Education | $276.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,569.60 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,546.21 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,013.25 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $831.76 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $822.76 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $624.59 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $620.32 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $478.13 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $395.07 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $330.40 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $274.44 | 2022-2025 | Perseris, Sublocade |
| Gilead Sciences, INC. | $114.79 | 2022-2023 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $113.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.61 | 2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $102.04 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $55.01 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.37 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.